Siegfried, a global CDMO for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience. The acquired businesses include three high-quality small molecules drug substances sites with approximately 400 employees: Noramco, a large, commercial-scale manufacturing site in Wilmington, DE  Purisys, a clinical API development and manufacturing facility in Athens, GA. ...